Literature DB >> 15259011

Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients.

Gal Markel1, Hagit Achdout, Gil Katz, Khoon-Lin Ling, Mariolina Salio, Raizy Gruda, Roi Gazit, Sa'ar Mizrahi, Jacob Hanna, Tsufit Gonen-Gross, Tal I Arnon, Niva Lieberman, Noam Stren, Boaz Nachmias, Richard S Blumberg, Guy Steuer, Hanna Blau, Vincenzo Cerundolo, Huda Mussaffi, Ofer Mandelboim.   

Abstract

Interactions of natural killer (NK) cells with MHC class I proteins provide the main inhibitory signals controlling NK killing activity. It is therefore surprising to learn that TAP2-deficient patients suffer from autoimmune manifestations only occasionally in later stages of life. We have previously described that the CEACAM1-mediated inhibitory mechanism of NK cytotoxicity plays a major role in controlling NK autoreactivity in three newly identified TAP2-deficient siblings. This novel mechanism probably compensates for the lack of MHC class I-mediated inhibition. The CEACAM1 protein can also be present in a soluble form and the biological function of the soluble form of CEACAM1 with regard to NK cells has not been investigated. Here we show that the homophilic CEACAM1 interactions are abrogated in the presence of soluble CEACAM1 protein in a dose-dependent manner. Importantly, the amounts of soluble CEACAM1 protein detected in sera derived from the TAP2-deficient patients were dramatically reduced as compared to healthy controls. This dramatic reduction does not depend on the membrane-bound metalloproteinase activity. Thus, the expression of CEACAM1 and the absence of soluble CEACAM1 observed in the TAP2-deficient patients practically maximize the inhibitory effect and probably help to minimize autoimmunity in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259011     DOI: 10.1002/eji.200425021

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  CEACAM1 structure and function in immunity and its therapeutic implications.

Authors:  Walter M Kim; Yu-Hwa Huang; Amit Gandhi; Richard S Blumberg
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

2.  Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease progression.

Authors:  Kiera L Clayton; Matthew B Douglas-Vail; A K M Nur-ur Rahman; Karyn E Medcalf; Irene Y Xie; Glen M Chew; Ravi Tandon; Marion C Lanteri; Philip J Norris; Steven G Deeks; Lishomwa C Ndhlovu; Mario A Ostrowski
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

Review 3.  Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells.

Authors:  Nathalie T Joncker; David H Raulet
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

4.  Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Authors:  Sydney X Lu; Lucy W Kappel; Anne-Marie Charbonneau-Allard; Renée Atallah; Amanda M Holland; Claire Turbide; Vanessa M Hubbard; Jimmy A Rotolo; Marsinay Smith; David Suh; Christopher King; Uttam K Rao; Nury Yim; Johanne L Bautista; Robert R Jenq; Olaf Penack; Il-Kang Na; Chen Liu; George Murphy; Onder Alpdogan; Richard S Blumberg; Fernando Macian; Kathryn V Holmes; Nicole Beauchemin; Marcel R M van den Brink
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

Review 5.  Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.

Authors:  Sivan Sapoznik; Ohad Hammer; Rona Ortenberg; Michal J Besser; Tehila Ben-Moshe; Jacob Schachter; Gal Markel
Journal:  Clin Dev Immunol       Date:  2012-04-23

6.  Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.

Authors:  R Ortenberg; S Sapoznik; D Zippel; R Shapira-Frommer; O Itzhaki; A Kubi; D Zikich; M J Besser; J Schachter; G Markel
Journal:  J Immunol Res       Date:  2015-11-25       Impact factor: 4.818

Review 7.  CEACAM1 as a multi-purpose target for cancer immunotherapy.

Authors:  Matthew Dankner; Scott D Gray-Owen; Yu-Hwa Huang; Richard S Blumberg; Nicole Beauchemin
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

Review 8.  SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.

Authors:  Wei-Sheng Tien; Jun-Hong Chen; Kun-Pin Wu
Journal:  BMC Bioinformatics       Date:  2017-03-14       Impact factor: 3.169

9.  Increased CD4(+) T cell co-inhibitory immune receptor CEACAM1 in neonatal sepsis and soluble-CEACAM1 in meningococcal sepsis: a role in sepsis-associated immune suppression?

Authors:  Michiel van der Flier; Dyana B Sharma; Silvia Estevão; Marieke Emonts; Denise Rook; Jan A Hazelzet; Johannes B van Goudoever; Nico G Hartwig
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

10.  CEACAM1-Mediated Inhibition of Virus Production.

Authors:  Alon Vitenshtein; Yiska Weisblum; Sebastian Hauka; Anne Halenius; Esther Oiknine-Djian; Pinchas Tsukerman; Yoav Bauman; Yotam Bar-On; Noam Stern-Ginossar; Jonatan Enk; Rona Ortenberg; Julie Tai; Gal Markel; Richard S Blumberg; Hartmut Hengel; Stipan Jonjic; Dana G Wolf; Heiko Adler; Robert Kammerer; Ofer Mandelboim
Journal:  Cell Rep       Date:  2016-06-02       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.